These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 26415523)

  • 21. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.
    Niemann M; Rolfs A; Störk S; Bijnens B; Breunig F; Beer M; Ertl G; Wanner C; Weidemann F
    Circ Cardiovasc Genet; 2014 Feb; 7(1):8-16. PubMed ID: 24395922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional and biological studies of α-galactosidase A variants with uncertain significance from newborn screening in Taiwan.
    Liao HC; Hsu TR; Young L; Chiang CC; Huang CK; Liu HC; Niu DM; Chen YJ
    Mol Genet Metab; 2018 Feb; 123(2):140-147. PubMed ID: 28615118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late-onset and classic phenotypes of Fabry disease in males with the
    Valtola K; Hedman M; Kantola I; Walls S; Helisalmi S; Maria M; Raivo J; Auray-Blais C; Kuusisto J
    Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
    Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
    Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
    Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
    Talbot A; Nicholls K; Fletcher JM; Fuller M
    Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
    Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
    EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational analysis of the GLA gene in Mexican families with Fabry disease.
    Gutiérrez-Amavizca BE; Gal A; Ortíz-Orozco R; Orth U; Prado Montes De Oca E; Gutiérrez-Amavizca JP; Figuera LE
    J Genet; 2017 Mar; 96(1):161-164. PubMed ID: 28360401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.
    Varela P; Carvalho G; Martin RP; Pesquero JB
    Metab Brain Dis; 2021 Feb; 36(2):265-272. PubMed ID: 33156427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Screening Test of Fabry Disease in Patients with Renal Replacement Therapy in the City of Modena].
    Alfano G; Ganda N; Cerami C; Mori G; Fontana F; Cappelli G
    G Ital Nefrol; 2018 Mar; 35(2):. PubMed ID: 29582965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ.
    Ferri L; Malesci D; Fioravanti A; Bagordo G; Filippini A; Ficcadenti A; Manna R; Antuzzi D; Verrecchia E; Donati I; Mignani R; Cavicchi C; Guerrini R; Morrone A
    Clin Chim Acta; 2018 Jun; 481():25-33. PubMed ID: 29476735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional Characterization and Pharmacological Evaluation of a Novel GLA Missense Mutation Found in a Severely Affected Fabry Disease Family.
    Varela P; Mastroianni Kirsztajn G; Ferrer H; Aranda C; Wallbach K; Ferreira da Mata G; Moura LA; Moreira SR; Mendes C; Curiati MA; Martins AM; Bosco Pesquero J
    Nephron; 2020; 144(3):147-155. PubMed ID: 31665721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
    Park JY; Kim GH; Kim SS; Ko JM; Lee JJ; Yoo HW
    Exp Mol Med; 2009 Jan; 41(1):1-7. PubMed ID: 19287194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance.
    van der Tol L; Smid BE; Poorthuis BJ; Biegstraaten M; Deprez RH; Linthorst GE; Hollak CE
    J Med Genet; 2014 Jan; 51(1):1-9. PubMed ID: 23922385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
    Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
    Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype-Phenotype Correlations in 293 Russian Patients with Causal Fabry Disease Variants.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Pakhomov A; Trufanova E; Alexeeva A; Sladkov D; Kuzenkova L; Asanov A; Fisenko A
    Genes (Basel); 2023 Oct; 14(11):. PubMed ID: 38002959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variants of unknown significance in alpha-galactosidase A: Cellular delineation from Fabry disease.
    Klein A; Klug K; Breyer M; Grüner J; Medala VK; Nordbeck P; Wanner C; Klopocki E; Üçeyler N
    J Inherit Metab Dis; 2024 Jul; 47(4):805-817. PubMed ID: 38618884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
    Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA
    PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.
    Kobayashi M; Ohashi T; Fukuda T; Yanagisawa T; Inomata T; Nagaoka T; Kitagawa T; Eto Y; Ida H; Kusano E
    Mol Genet Metab; 2012 Dec; 107(4):711-5. PubMed ID: 23146289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.